TransMedics Group, Inc. (TMDX)
TMDXNASDAQ-GMBiotechnology: Electromedical & Electrotherapeutic Apparatus
$91.50
-0.5100 (-0.55%) today
At the close, Nov 11, 4:00 PM ET. Pre-market $91.50 -0.55%
- Market cap
- $3.18bn
- P/E
- 50.3
- EPS, last 4 quarters
- $1.82
- Dividend yield
- –
- Day range
- –
- 52-week range
- $60.11 to $156.00
- Average volume
- –
- Previous close
- $92.01
Analysts
10 coveringBuy7 buy, 3 hold, 0 sell
Targets a year out average $102.89, +12.4% from here
Earnings
next estimate $0.4100Next report
Dec 2025
+39.0%
Mar 2026
-51.6%
Jun 2026
-12.0%
Sep 2026
+88.9%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $160.76m | $173.93m | $189.95m | $203.00m |
| Gross profit | $93.41m | $101.16m | $113.20m | $118.66m |
| Operating income | $21.27m | $13.30m | $23.74m | $28.14m |
| Net income | $105.38m | $7.32m | $14.68m | $17.07m |
Last four quarters: revenue $727.65m, margin 19.9%, free cash flow $44.70m
News
8 latest- TransMedics (TMDX) Just Reclaimed the 200-Day Moving AverageZacks · 1 day ago
- TransMedics: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · 2 days ago
- TransMedics (TMDX) Just Flashed Golden Cross Signal: Do You Buy?Zacks · 3 days ago
- TransMedics (TMDX) Recently Broke Out Above the 50-Day Moving AverageZacks · 3 days ago
- TransMedics Group Q3 Earnings Call HighlightsMarketBeat · 6 days ago
- Noteworthy Friday Option Activity: CCSI, TMDX, MSFTBNK Invest · 6 days ago
- Healthcare Stocks Advance: OBX Surges 38%, ONCO Gains 32%, TMDX Rises 26% RTTNews · 6 days ago
- TransMedics Reports Third Quarter 2026 Financial ResultsFintel · 6 days ago
The company
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- transmedics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.